Dendritic Cells Targeting Flt3 Ligand As Molecular Mucosal Adjuvant

抄録

Nasal antigen plus mucosal adjuvant delivery has emerged as perhaps the most effective route for induction of both mucosal and peripheral immune response. It has been shown that dendritic cells (DCs) played essential roles for the induction of both immunity and tolerance. Thus, nasal application of CpG ODN targeting plasmacytoid DCs effectively induced antigen-specific immunity. Our recent studies showed that nasal or oral immunization with protein antigen, ovalbumin plus plasmid encoding Flt3 ligand (pFL) cDNA as adjuvant effectively elicited OVA-specific immune responses in both mucosal and systemic lymphoid tissues. The numbers of (DCs) in mice given pFL as mucosal adjuvant were significantly increased. Further, these expanded DCs were activated and expressed MHC II and co-stimulatory molecules (CD40, CD80 and CD86). These results show that mucosal delivery of pFL is DCs targeting adjuvant system that effectively induce both mucosal and systemic antigen-specific immune responses.